+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bone Marrow Transplant Rejection - Pipeline Review, H2 2019

  • ID: 4866517
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 696 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • enGene Inc
  • Incyte Corp
  • Medeor Therapeutics Inc
  • SCM lifescience Co Ltd
  • MORE
Bone Marrow Transplant Rejection - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2019, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 39, 13, 2, 49, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • enGene Inc
  • Incyte Corp
  • Medeor Therapeutics Inc
  • SCM lifescience Co Ltd
  • MORE
Introduction
Bone Marrow Transplant Rejection - Overview
Bone Marrow Transplant Rejection - Therapeutics Development
Bone Marrow Transplant Rejection - Therapeutics Assessment
Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
Bone Marrow Transplant Rejection - Drug Profiles
Bone Marrow Transplant Rejection - Dormant Projects
Bone Marrow Transplant Rejection - Discontinued Products
Bone Marrow Transplant Rejection - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Bone Marrow Transplant Rejection, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Universities/Institutes, H2 2019
Table 9: Products under Development by Companies, H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 17: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 18: Products under Development by Universities/Institutes, H2 2019
Table 19: Number of Products by Stage and Target, H2 2019
Table 20: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 21: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 22: Number of Products by Stage and Mechanism of Action, H2 2019
Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 25: Number of Products by Stage and Route of Administration, H2 2019
Table 26: Number of Products by Stage and Molecule Type, H2 2019
Table 27: Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H2 2019
Table 28: Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H2 2019
Table 29: Bone Marrow Transplant Rejection - Pipeline by Adienne Pharma & Biotech, H2 2019
Table 30: Bone Marrow Transplant Rejection - Pipeline by Alpine Immune Sciences Inc, H2 2019
Table 31: Bone Marrow Transplant Rejection - Pipeline by Amgen Inc, H2 2019
Table 32: Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H2 2019
Table 33: Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H2 2019
Table 34: Bone Marrow Transplant Rejection - Pipeline by ASC Therapeutics Inc, H2 2019
Table 35: Bone Marrow Transplant Rejection - Pipeline by AstraZeneca Plc, H2 2019
Table 36: Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H2 2019
Table 37: Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
Table 38: Bone Marrow Transplant Rejection - Pipeline by Biocon Ltd, H2 2019
Table 39: Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H2 2019
Table 40: Bone Marrow Transplant Rejection - Pipeline by BioIncept LLC, H2 2019
Table 41: Bone Marrow Transplant Rejection - Pipeline by BlueRock Therapeutics, H2 2019
Table 42: Bone Marrow Transplant Rejection - Pipeline by Boryung ViGenCell Inc, H2 2019
Table 43: Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 44: Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H2 2019
Table 45: Bone Marrow Transplant Rejection - Pipeline by Celgene Corp, H2 2019
Table 46: Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H2 2019
Table 47: Bone Marrow Transplant Rejection - Pipeline by Cellect Biotechnology Ltd, H2 2019
Table 48: Bone Marrow Transplant Rejection - Pipeline by Cellective BioTherapy Inc, H2 2019
Table 49: Bone Marrow Transplant Rejection - Pipeline by Cellix Bio Pvt Ltd, H2 2019
Table 50: Bone Marrow Transplant Rejection - Pipeline by CheckPoint Immunology Inc, H2 2019
Table 51: Bone Marrow Transplant Rejection - Pipeline by Clinigen Group Plc, H2 2019
Table 52: Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H2 2019
Table 53: Bone Marrow Transplant Rejection - Pipeline by CSL Ltd, H2 2019
Table 54: Bone Marrow Transplant Rejection - Pipeline by CTI BioPharma Corp, H2 2019
Table 55: Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H2 2019
Table 56: Bone Marrow Transplant Rejection - Pipeline by Cytopeutics Pte Ltd, H2 2019
Table 57: Bone Marrow Transplant Rejection - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Table 58: Bone Marrow Transplant Rejection - Pipeline by Dualogics Corp, H2 2019
Table 59: Bone Marrow Transplant Rejection - Pipeline by Eli Lilly and Co, H2 2019
Table 60: Bone Marrow Transplant Rejection - Pipeline by Elsalys Biotech SA, H2 2019

List of Figures
Figure 1: Number of Products under Development for Bone Marrow Transplant Rejection, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • AbGenomics International Inc
  • Adienne Pharma & Biotech
  • Alpine Immune Sciences Inc
  • Amgen Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • ASC Therapeutics Inc
  • AstraZeneca Plc
  • Athersys Inc
  • Bellicum Pharmaceuticals Inc
  • Biocon Ltd
  • Biogen Inc
  • BioIncept LLC
  • BlueRock Therapeutics
  • Boryung ViGenCell Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Celgene Corp
  • Cell Source Inc
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • Cellix Bio Pvt Ltd
  • CheckPoint Immunology Inc
  • Clinigen Group Plc
  • Compugen Ltd
  • CSL Ltd
  • CTI BioPharma Corp
  • Cytodyn Inc
  • Cytopeutics Pte Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dualogics Corp
  • Eli Lilly and Co
  • Elsalys Biotech SA
  • enGene Inc
  • Enlivex Therapeutics Ltd
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corp
  • Generon (Shanghai) Corp Ltd
  • GlaxoSmithKline Plc
  • Glia LLC
  • Heat Biologics Inc
  • Humanigen Inc
  • Immplacate
  • Immune Modulation Inc
  • ImmuneTarget Inc
  • Imstem Biotechnology Inc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • ITB-Med AB
  • Jazz Pharmaceuticals Plc
  • JN Biosciences LLC
  • Kadmon Corp LLC
  • Kalytera Therapeutics Inc
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kiniksa Pharmaceuticals Corp
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • Machavert Pharmaceuticals LLC
  • Magenta Therapeutics Inc
  • Mallinckrodt Plc
  • Medac Pharma Inc
  • Medeor Therapeutics Inc
  • Medicenna Therapeutics Corp
  • Medsenic SAS
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • NapaJen Pharma Inc
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Ocugen Inc
  • OncoImmune Inc
  • OSE Immunotherapeutics
  • Panorama Research Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • Precision Biosciences Inc
  • REGiMMUNE Corp
  • Sanofi
  • SCM lifescience Co Ltd
  • Seattle Genetics Inc
  • Secura Bio Inc
  • Seres Therapeutics Inc
  • STERO Biotechs Ltd
  • Suzhou Connect Biopharmaceuticals Ltd
  • Syndax Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Taiwan Bio Therapeutics Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TCF GmbH
  • TeraImmune Inc
  • TGV Laboratories Inc
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Visterra Inc
  • Xenikos BV
  • Xenothera SAS
  • XL-protein GmbH
Note: Product cover images may vary from those shown
Adroll
adroll